ClinicalTrials.gg
CompletedNCT03273790Updated Feb 3, 2022

A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan

An observational study in Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 1 site in Japan. Per ClinicalTrials.gov, last updated 2022-02-03.

Sponsored by Bristol-Myers Squibb · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
939
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb — 21 open to participants now, 35 under way, 10 of them phase 3. Carcinoma, Non-Small-Cell Lung · Bristol-Myers Squibb.

Enrollment
3rd of 21
939 · median 404
Started
2017
with 8 others
Observational
21 of 131
2 open now
Registered
65th of 131
by date

Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one is the 3rd largest by enrollment of the 21 observational ones that give a count, is one of 9 that started in 2017, is one of 21 observational ones, and was the 65th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Previously treated advanced/metastatic NSCLC patients treated with nivolumab in Japan.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously treated advanced/ NSCLC patients treated with nivolumab at least once from 01-Apr-2016 through 31-Dec-2016

Exclusion criteria

Exclusion Criteria:

Patients who meets the inclusion criteria will be included in the analysis to describe real-world clinical usage of nivolumab. However, patients treated with nivolumab falling in following criteria will be excluded for analysis for the other primary endpoint; overall effectiveness:

  • History of participation in any clinical trials prior- or post-nivolumab treatment
  • Patients who are a part of a Post-marketing surveillance study

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
939 participants (actual)
Patient registry
No

Groups and cohorts

  • NSCLC patients

    Initiated Nivolumab treatment at least once from 01 Apr. 2016 through 31 Dec. 2016

This study also gives Nivolumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Description of clinical usage of nivolumab in previously treated NSCLC patients

    Time frame: Approximately 9 months

  2. Overall Survival (OS)

    Measured from time of initial diagnosis and treatment with nivolumab until date of death

    Time frame: Approximately 9 months

  3. Progression Free Survival (PFS)

    Time since index date (initial diagnosis and treatment with nivolumab) to either the first disease progression date or last known tumor assessment date, or death due to any cause, whichever occurs first

    Time frame: Approximately 9 months

Secondary outcomes

  1. Percentage of patients receiving bi-weekly nivolumab

    Time frame: Approximately 9 months

  2. Percentage of patients receiving monotherapy or combination therapy

    Time frame: Approximately 9 months

  3. Percentage of patients receiving nivolumab as second or later line of therapy

    Time frame: Approximately 9 months

  4. Median treatment duration and range by line and histology

    Time frame: Approximately 9 months

  5. Rate of permanent and temporary discontinuations

    Time frame: Approximately 9 months

  6. Reasons for discontinuation of nivolumab

    Time frame: Approximately 9 months

  7. Reasons for re-challenge of nivolumab

    Time frame: Approximately 9 months

  8. Objective Response Rate (ORR) as assessed by investigator

    ORR is defined as the number of participants with best overall response (OR) of confirmed complete response (CR) or partial response (PR) divided by the total number of participants who received treatment

    Time frame: Approximately 9 months

07

Study locations

1 site
  • Local Institution
    Minato-ku, Tokyo 1050001, Japan
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in Dec 2017, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2017
First posted
Sep 6, 2017
StartActual
Apr 1, 2017
Primary completionActual
Dec 31, 2017
CompletionActual
Dec 31, 2018
Last update
Feb 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03273790
Responsible party
Sponsor
First posted
Sep 6, 2017
Start date
Apr 1, 2017
Primary completion
Dec 31, 2017
Completion
Dec 31, 2018
Last update
Feb 3, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion